



TRANSFORMATION. UNLOCKED.

ElixirMedical.com


Elixir Medical Corporation
920 N McCarthy Blvd.
Milpitas, CA 95035
www.elixirmedical.com


For OUS distribution only



PMN 1626 Rev D

THE FUTURE OF VASCULAR
INTERVENTION WON'T JUST EVOLVE,
IT WILL ADAPT.





EVOLVING PCI
BY FOLLOWING
NATURE'S BLUEPRINT


*LETTING VESSELS
FUNCTION AS INTENDED*



BREAKTHROUGH RESULTS IN CAD TREATMENT

*SUSTAINED CLINICAL BENEFIT POWERED
BY THE NOVEL MECHANISM OF ACTION*


Significant TLF reduction at **2-years** versus
Resolute Onyx DES¹



SIGNIFICANCE WHERE IT MATTERS MOST

*RESTORING VESSEL VIABILITY LEADS
TO OUTSTANDING CLINICAL BENEFITS*

Significant TLF reduction at **2-years** in LAD
lesions versus Resolute Onyx DES¹





THE UNCOMFORTABLE TRUTH OF LIFE-LONG STENTING

*PERMANENT CAGING OF VESSELS LEAVES
PATIENTS AT RISK OF LATE EVENTS¹*


Drug-eluting stents have shown

>50%

**lifetime risk of stent-related
Major Adverse Cardiac Events¹**

Reinforced by findings showing ongoing risk of about 2%
a year at least through 5-year follow-up with no sign of
plateau, irrespective of stent type²

Caging natural vascular motion and physiology can
contribute to stent fractures, restenosis, myocardial



The heart is a dynamic, pulsating,
living organ, arteries are no different.
They do what they need to adapt to
the heart's changing demands and
sustain life.

Three-dimensional vasomotion

To meet the demands of every heartbeat

Pulsatility


To help maintain blood flow and pressure³

Positive adaptive remodeling

To mitigate against disease progression³



THE ESSENTIALS OF *TRIPLE STAGE THERAPY*



Opening horizons in coronary interventions and early treatments for long-term outcomes. Welcome to the new natural state where technology works with the vessel, and not against it.

¹RESTORE *FLOW*

First step in any intervention is restoring blood flow. And, with DynamX® you will establish maximum flow lumen and restore blood flow without compromising the ability for the vessel to naturally heal.¹

²RELEASE *VESSEL*

After 6 months the magic happens. DynamX unlocks itself, releasing the vessel while maintaining the established lumen flow.¹


³RETURN *FUNCTION*

Finally, the vessel returns back to its natural physiology, motion and function. The final phase provides continuing adaptive dynamic support to restore vessel hemodynamic modulation through restoration of pulsatility and adaptive blood flow volume and has shown evidence of plaque stabilization and regression in the lesion.¹

1. Saito S, et al. BIOADAPTOR RCT 12-month clinical and imaging data. eClinicalMedicine Lancet 2023



THE DYNAMX BIOADAPTOR: *LEAVING THE RIGHT THING BEHIND*



¹ LOCKED

Interlocked CoCr helical strands, fused by PLLA basecoat provide radial strength

Maximum flow lumen established and blood flow restored


² UNLOCK AND SEPARATE

3-month resorption of polymer top coat and release of 'timus' drug enables optimal healing and thin neointima formation

Controlled resorption of basecoat polymer over 6 months enables

³ ADAPTIVE DYNAMIC SUPPORT


Separated helical strands provide continuing adaptive dynamic support to restore vessel hemodynamic modulation through restoration of pulsatility and adaptive blood flow volume restored





DYNAMX UNLOCKS TO
RELEASE THE VESSEL
*RESTORING POSITIVE ADAPTIVE
REMODELING AND MAINTAINING
ESTABLISHED LUMEN PATENCY*

Significantly lower late lumen loss, especially in
vessels and lesions at high risk of restenosis¹



Bioadaptor: LLL in overall cohort and subgroups

MAINTAINING
*FLOW LUMEN**

Superior flow lumen maintained
across vessel types¹



LIFE DOESN'T STAND STILL.
AND NOR SHOULD VESSELS.

*ONLY DYNAMX RESTORES
HEMODYNAMIC MODULATION
AND PULSATILITY*




Immediately post-procedure:

Pulsatility is constrained in both DynamX bioadaptor and DES (p=ns)¹



At 12-months:

DynamX bioadaptor is unlocked to establish pulsatility and lumen area changes with every heartbeat vs DES¹



THE DYNAMX FLOW EFFECT
*CHANGE IN BLOOD FLOW VOLUME
WITH EVERY HEARTBEAT*

↑ Pulsatility

7.5%

increase in lumen area
with every heartbeat

In-device % increase in lumen area:
2.7% (± 2.7) post-procedure and 7.5% (± 4.6)
at 12 months for DynamX¹

↑ Blood Flow

16.7%

increase in blood flow
volume with every heartbeat


Blood flow volume increase per heartbeat:
6.5% (± 0.6) post-procedure and 16.7% (± 1.3)
at 12 months for DynamX¹



Findings from a preplanned imaging subgroup analysis.
Lumen area changes and blood flow increase measured by IVUS (n=48
DynamX; n=47 DES). IVUS=intravascular ultrasound.
1. Saito S, et al. BIOADAPTOR RCT 12-month clinical and imaging data.
eClinicalMedicine Lancet 2023 ;

WITH SUPPORT, THE VESSEL RETURNS
TO ITS NATURAL STATE
THEN SOMETHING EXTRAORDINARY HAPPENS


Plaque volume behind DynamX is stabilized, while
increasing by 12% in the Resolute Onyx stent arm¹



% plaque volume change at 12 months (IVUS)

↓ 9%

Plaque volume regression in
lipid rich lesions with DynamX
vs. an increase with DES¹



An exploratory finding that points to a hypothesis of a synergistic effect
between restoration of vessel motion and function and systemic use of
lipid-lowering medications¹



DynamX® Coronary Bioadaptor System PRODUCT ORDERING INFORMATION

	Bioadaptor Length					
Bioadaptor Diameter	14mm	18mm	23mm	28mm	32mm	38mm
2.25mm	VCR2214	VCR2218	VCR2223	VCR2228	VCR2232	VCR2238
2.5mm	VCR2514	VCR2518	VCR2523	VCR2528	VCR2532	VCR2538
2.75mm	VCR2714	VCR2718	VCR2723	VCR2728	VCR2732	VCR2738
3.0mm	VCR3014	VCR3018	VCR3023	VCR3028	VCR3032	VCR3038
3.5mm	VCR3514	VCR3518	VCR3523	VCR3528	VCR3532	VCR3538
4.0 mm	VCR4015*	VCR4018	VCR4023	VCR4028	VCR4032	VCR4038

Not all sizes available in all geographies.

*VCR4015 is 15mm in length

MORE INFORMATION OR TO ORDER THE DYNAMX BIOADAPTOR

Contact your local sales representative or email us at Sales@elixirmedical.com

Elixir Medical Corporate Headquarters
920 N. McCarthy Blvd, Milpitas, CA 95035 USA
+1.408.636.2000
info@elixirmedical.com

Elixir, Innovation for Life, and DynamX are registered trademarks
in the US and internationally for Elixir Medical Corporation.

DynamX Novolimus Eluting Coronary Bioadaptor System is CE Mark approved.
©2023 Elixir Medical. All rights reserved. PMN 506 Rev F

www.ElixirMedical.com

